Walk-BEST for Osteoporosis

(Walk-BEST Trial)

This trial tests a new walking program called Walk-BEST™, designed to help older adults with osteoporosis improve their walking. The goal is to determine if this program is easy to use and acceptable for this group. Participants will either start the program immediately or after a 3-month delay. It suits those aged 70 and older who can walk independently, have experienced certain types of fractures or falls, or are on specific osteoporosis medications.

As an unphased trial, this study provides a unique opportunity to contribute to research that could enhance mobility and quality of life for older adults with osteoporosis.

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants can be on certain osteoporosis medications, so you might not need to stop those.

Research shows that the Walk-BEST™ program, which uses the Heel2Toe sensor, helps older adults with osteoporosis walk more safely and reduce falls. Studies have found that the Heel2Toe sensor can improve walking ability. In one study, 13 out of 14 participants improved their performance in a six-minute walk test. This suggests that the treatment is generally well-tolerated and might be safe to use.

Researchers are excited about Walk-BEST for osteoporosis because it introduces a novel approach to managing the condition. Unlike standard treatments that primarily focus on medication to increase bone density or slow bone loss, Walk-BEST incorporates a wearable Heel2Toe sensor to enhance walking patterns and balance. This method aims to reduce the risk of falls and fractures, which are common concerns for individuals with osteoporosis. By potentially improving mobility and safety through real-world walking interventions, Walk-BEST offers an innovative complement to existing pharmaceutical options.

Research has shown that the Walk-BEST™ technology, which uses the Heel2Toe sensor, improves walking in people with osteoporosis. In one study, 13 out of 14 participants walked farther and better in a six-minute test after using the Heel2Toe sensor. This trial will evaluate the Walk-BEST™ intervention, with some participants receiving it immediately and others after a 3-month delay. The technology provides real-time sound feedback to help users adjust their steps and reduce the risk of falling. Specifically, improvements were observed in both the distance and quality of walking, which is crucial for those with balance issues. Overall, these findings suggest that Walk-BEST™ can be a valuable tool for enhancing walking and reducing fall risk in older adults with osteoporosis.¹²³⁶⁷